Publication
Article
Pharmaceutical Technology
ADCC Expression Cell Line
Author(s):
The ADCC+ Cell Line is designed for rapid identification of clones expressing high levels of recombinant therapeutic proteins.
The ADCC+ Cell Line
PerkinElmer’s antibody-dependent cellular cytotoxicity (ADCC)+ Cell Line is an expression cell line for the company’s Horizon Discovery CHOSOURCE platform, which is designed for rapid identification of clones expressing high levels of recombinant therapeutic proteins.
The ADCC+ cell line eliminates the fucose gene to increase ADCC activity with the intent of improving the potency and efficacy of therapeutic antibodies and fusion protein biotherapeutics. At the same time, it aims to reduce dosage requirements and side effects for patients.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
